首页> 外文期刊>Artificial Organs >Efficacy of bone marrow mononuclear cells to promote bone regeneration compared with isolated CD34+ cells from the same volume of aspirate.
【24h】

Efficacy of bone marrow mononuclear cells to promote bone regeneration compared with isolated CD34+ cells from the same volume of aspirate.

机译:骨髓单核细胞促进骨再生与来自相同体积的吸气量相比促进骨再生的疗效。

获取原文
获取原文并翻译 | 示例
       

摘要

Autologous bone marrow mononuclear cell (BMMNC) transplantation is currently an emerging clinical treatment in the orthopedic as well as cardiovascular fields. It is believed that the therapeutic effect of the BMMNCs is due to neovascularization enhanced by the CD34(+) cells contained therein, which include endothelial progenitor cells. However, isolation of the CD34(+) cell fraction for clinical application has many disadvantages such as cost and invasiveness related to cell mobilization with cytokine. To investigate whether a purification step is in fact necessary for bone regeneration, we separated BMMNCs, CD34(+), and CD34(-) cells from the same initial volume of rabbit bone marrow aspirates. We then transplanted them back into a femoral bone defect of the same rabbit together with atelocollagen gel and basic fibroblast growth factor (bFGF) and evaluated neovascularization and bone regeneration up to 8 weeks after transplantation. The greatest potential for neovascularization and bone regeneration medicated by cells from the same volume of bone marrow aspirate was found in the BMMNC group. Although purified CD34(+) cells might be an ideal cell source, BMMNCs could be a practical and feasible cell source for bone regeneration in present clinical settings with limited cost, availability of materials, and technical issues for transplantation.
机译:自体骨髓单核细胞(BMMNC)移植目前是在整形外科以及心血管领域的新出现的临床治疗。据信,BMMNC的治疗效果是由于其中包含的CD34(+)细胞增强的新血管形成,其包括内皮祖细胞。然而,用于临床应用的CD34(+)细胞级分的分离具有许多缺点,例如与细胞因子的细胞动员有关的成本和侵袭性。为了研究纯化步骤是否实际上是骨再生所必需的,我们将BMMNCS,CD34(+)和CD34( - )细胞分离出来自兔骨髓抽吸物的相同初始体积。然后,我们将它们移植回到与Etelocollagen凝胶和碱性成纤维细胞生长因子(BFGF)的股骨骨缺损,并在移植后8周评价的新生血管和骨再生。在BMMNC组中发现了由来自相同体积的骨髓抽吸物中细胞的新血管化和骨再生的最大潜力。虽然纯化的CD34(+)细胞可能是理想的细胞源,但BMMNC可能是目前临床环境中的骨再生的实用性和可行的细胞来源,其具有有限的成本,材料的可用性以及移植的技术问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号